Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years
This was a post hoc analysis evaluating adverse event (AE) data of semaglutide in people ≥ 65 years.The most common AE with semaglutide was gastrointestinal (GI).GI event rates were similar in people ≥ 65 years and the overall study populations.
Authors
- Vanita R. Aroda (ORCID: https://orcid.org/0000-0002-7706-4585)
- Sune Dandanell (ORCID: https://orcid.org/0000-0001-6412-2507)
- Magnus Fugger
- Cristina Boschini (ORCID: https://orcid.org/0000-0001-6905-7038)
- Sue D. Pedersen (ORCID: https://orcid.org/0000-0002-4355-1764)
- Luis Rafael Solís Tarazona (ORCID: https://orcid.org/0000-0002-0921-3745)
- Frank Jessen (ORCID: https://orcid.org/0000-0003-1067-2102)
- Marwan N. Sabbagh (ORCID: https://orcid.org/0000-0001-8139-3309)
- Sharon Cohen (ORCID: https://orcid.org/0000-0001-9955-940X)
Institutions
- Brigham and Women's Hospital (US)
- Barrow Neurological Institute (US)
- Harvard University (US)
- Novo Nordisk (Denmark) (DK)
- LMC Diabetes & Endocrinology (Canada) (CA)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70076
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Novo Nordisk